We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Actavis, Inc. | NYSE:WPI | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 85.73 | 0.00 | 01:00:00 |
From Apr 2019 to Apr 2024
WASHINGTON--The Federal Trade Commission on Monday cleared Watson Pharmaceuticals Inc.'s (WPI) proposed $5.9 billion acquisition of Swiss rival Actavis, but required the companies to sell the rights and assets to 18 drugs as a condition of government approval.
Under a settlement with the FTC, the companies will sell those assets to Sandoz International GmbH and Par Pharmaceutical Inc., the agency said.
The FTC also said Watson and Actavis will relinquish manufacturing and marketing rights to three other drugs.
The agency said the settlement would protect competition in the markets for current and future generic drugs used to treat a wide range of conditions, from diabetes to anxiety and attention deficit hyperactivity disorder.
Write to Brent Kendall at brent.kendall@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Watson Chart |
1 Month Watson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
